TWD 179.0
(-1.65%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 606.06 Million TWD | 31.19% |
2022 | 461.98 Million TWD | 58.92% |
2021 | 290.69 Million TWD | 8.7% |
2020 | 267.43 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 634.6 Million TWD | 4.71% |
2024 Q2 | 667.4 Million TWD | 5.17% |
2023 Q4 | 606.06 Million TWD | 1.45% |
2023 FY | 606.06 Million TWD | 31.19% |
2023 Q1 | 508.37 Million TWD | 10.04% |
2023 Q3 | 597.39 Million TWD | 8.88% |
2023 Q2 | 548.67 Million TWD | 7.93% |
2022 Q4 | 461.98 Million TWD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 705.32 Million TWD | 14.072% |
Maxigen Biotech Inc. | 85.18 Million TWD | -611.472% |
SciVision Biotech Inc. | 87.25 Million TWD | -594.617% |
Bionime Corporation | 491.25 Million TWD | -23.37% |
Pegavision Corporation | 583.47 Million TWD | -3.871% |